In premarket trading, shares of biopharmaceutical company developing engineered NK cell therapies to treat cancer Nkarta Inc. (NASDAQ: NKTX) rose 14.62% to $29.71 at last check. Last session, Nkarta closed at $25.92, decreasing by -5.30% or $1.45. In the course of the day, price of NKTX stock fluctuated in the range from $24.50 to $27.23. On news of strategic oncology research collaboration, NKTX stock has been rising.
What is the collaboration for?
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Biotech company Nkarta is developing natural killer (NK) cell therapy for the treatment of cancer with allogeneic tissue. Through the combination of its cell expansion and cryopreservation platform with proprietary cell engineering technologies, NKTX is developing a pipeline of cell therapy candidates that can help patients by improving the cell’s targeting ability and persistence in the body.
Read More
Nkarta and CRISPR Therapeutics have announced yesterday a strategic partnership for the development, research, and commercialization of CRISPR/Cas9 gene-edited cell therapies specifically for cancer.
- As a result of the agreement, NKTX will work together with CRISPR to co-produce and co-market two CAR-NK cell candidates, one targeting the CD70 tumor antigen and second a to-be-determined target.
- In addition, NKTX will combine its skills in cell therapy engineering and manufacturing with that of CRISPR to further develop a novel NK+T product candidate harnessing synergistic effects of the immune system’s innate and adaptive components.
- Last but not least, NKTX obtains a license to CRISPR gene-editing technology that can edit 5 gene targets in a multitude of their own NK cell therapy products.
How the collaboration will work?
Nkarta (NKTX) and CRISPR will share equally all R&D and profits related to the collaboration products worldwide. NKTX will hold worldwide rights to every non-collaboration product candidate that incorporates a CRISPR Therapeutics gene-editing target, and will pay CRISPR Therapeutics on net sales for product milestones and royalties.